62019-71-0

Usage

Uses

Used in Pharmaceutical Synthesis:
4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE is used as a building block for the synthesis of various pharmaceuticals due to its ability to contribute to the development of novel drug molecules with potential therapeutic effects.
Used in Agrochemical Production:
In the agrochemical industry, 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE is used as a key component in the creation of new agrochemicals, leveraging its structural properties to enhance crop protection and yield.
Used in Organic Synthesis:
4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE is utilized as a reagent in organic synthesis, particularly for the production of heterocyclic compounds, which are important in various chemical and pharmaceutical applications.
Used in Drug Development:
4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE is employed as a potential drug candidate for the treatment of various diseases, including cancer and neurological disorders, owing to its demonstrated biological activity and potential therapeutic effects.

Upstream product

• 59311-67-0 2-(3-thienyl)ethylamine 
• 50-00-0 formaldehyd 

Downstream Products

• 165947-51-3 6-(tert-butoxycarbonyl)-4,5,6,7-tetrahydrothieno [2,3-c]pyridine-2-carboxylic acid 
• 1396841-05-6 methyl (S)-(+)-2-(2-chlorophenyl)-2-(4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)acetate 
• 144750-52-7 methyl 2-(2-chlorophenyl)-2-(4,5-dihydrothieno[2,3-c]pyridine-6(7H)-yl)acetate hydrochloride 
• 1396607-35-4 methyl (S)-(+)-2-(2-chlorophenyl)-2-(4,5-dihydrothieno[2,3-c]pyridine-6(7H)-yl)acetate hydrochloride 
• 144457-43-2 methyl 2-(2-chlorophenyl)-2-(4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)acetate 
• 165947-52-4 6-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine 
• 1428257-90-2 C₁₆H₁₃Cl₂N₃OS 
• 1428257-89-9 C₁₆H₁₄FN₃OS 
• 1428257-86-6 C₁₆H₁₅N₃O₂S 
• 1428257-85-5 C₁₈H₁₉N₃O₃S 
• 1428257-84-4 C₁₆H₁₃Cl₂N₃OS 
• 1428257-83-3 C₁₆H₁₄ClN₃OS 
• 1428257-82-2 C₁₆H₁₅N₃O₃S 
• 1428257-81-1 C₁₇H₁₇N₃O₂S 

Relevant academic research and scientific papers

Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.

Synthesis and characterization of impurity B of S-(+)-clopidogrel bisulfate: An antiplatelet

S-(+)-Clopidogrel bisulfate [(S-(+)-methyl 2-(2-chlorophenyl)-2-(6, 7-dihydrothieno[3, 2-c]pyridin-5(4H)-yl)acetate bisulfate)] is a platelet aggregation inhibitor drug. S-(+)-Clopidogrel bisulfate is prepared by different synthetic approaches in the literature. In almost all the approaches the major impurities known in the literature (A, B, and C) are also listed in the U.S. pharmacopoeia. The control of these pharmaceutical impurities is currently a critical issue to the pharmaceutical industry. In this article, a description of these impurities and their origins in the S-(+)-clopidogrel bisulfate process are presented along with the preparation of impurity B.